CD274 and small cell lung carcinoma: The identification of predictors of responses to immunotherapy is of extreme clinical importance since the addition of an anti-programmed death-ligand 1 (anti PD-L1) to the platinum–etoposide backbone represents the new standard of care for frontline treatment of ED-SCLC, regardless of PD-L1 or any other biomarker [4,5].